NCT06929507 Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
| NCT ID | NCT06929507 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Alexandroupolis |
| Condition | Renal Function Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2026-03-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-03-10 with a primary completion date of 2026-03-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.
Eligibility Criteria
Inclusion Criteria: * Patients with diabetes * Patients with DME or nAMD or macular edema secondary to retinal vein occlusion * Patients already receiving nephroprotective drugs Exclusion Criteria: * Patients with end stage renal disease * Pregnancy * Patients with other retinal disorders * Previous renal transplantation Patients under hemodialysis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06929507 clinical trial?
This trial is open to participants of all sexes, studying Renal Function Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06929507 currently recruiting?
Yes, NCT06929507 is actively recruiting participants. Contact the research team at asli_perende-90@hotmail.com for enrollment information.
Where is the NCT06929507 trial being conducted?
This trial is being conducted at Alexandroupoli, Greece, Alexandroupoli, Greece.
Who is sponsoring the NCT06929507 clinical trial?
NCT06929507 is sponsored by University Hospital, Alexandroupolis. The trial plans to enroll 60 participants.